Eli Lilly didn’t wake up to a good day on Monday as shares plummeted after it was revealed that the Food and Drug Administration (FDA) has rejected the company’s drug baricitinib, to treat rheumatoid arthritis. Shares closed down more than 4% while shares of Incyte, Lilly’s partner on the drug, closed down almost 11%. According … Continue reading “Eli Lilly Shares Fall After FDA Rejection”
